ATOPIC DERMATITIS (AD)

This study tests an experimental drug called BFB759, a lab-made antibody that blocks several inflammatory signals at once. Researchers want to see if it can reduce redness, swelling, and itching in adults with moderate-to-severe eczema that hasn't improved with creams. About 225 …

This early-stage trial tests the safety of a new drug called GB-7624 in 40 healthy adults. It is the first time this drug is being given to humans. The study gives single or multiple doses under the skin to see if it is safe and how the body processes it. If successful, it may ev…

This Phase 3 trial is testing an experimental oral drug called QY201 in 460 adults with moderate to severe atopic dermatitis (eczema). Participants will take either QY201 or a placebo daily for 16 weeks. The main goals are to see if the drug can significantly clear the skin and r…

This study tests whether wearing menthol-infused gloves and foot-covers for just five minutes a day can reduce itching in people with atopic dermatitis (eczema). Participants will use the gloves five days on, two days off for four weeks, then stop for two weeks of follow-up. The …

This early-stage study tests a new drug called ATTO-3712 in healthy adults and people with atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored with clinic visi…

This study tests whether a cream with 2% cholesterol can help repair the skin barrier and reduce symptoms in children aged 7-17 with mild to moderate eczema. Thirty participants will apply either the cholesterol cream or a placebo twice daily for 12 weeks. Researchers will measur…

This early-stage study tests a new drug called ATTO1310 to see if it is safe and how the body processes it. It includes healthy adults, people with atopic dermatitis (eczema), and those with long-term itching. Participants receive either the drug or a placebo and are monitored fo…

This study tests an experimental oral drug called HSK44459 in 150 adults with moderate-to-severe atopic dermatitis (eczema). Participants take the drug or a placebo twice daily for 12 weeks. The goal is to see if the drug safely reduces skin redness, swelling, and itch better tha…